Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (241-250 of 461) with videos related to

Pageof 47
Sort By:
Journal of the American Academy of Dermatology|July 17, 2017
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)Andrew Blauvelt, Kim A Papp, Mark G Lebwohl, et al.
Journal of Cutaneous Medicine and Surgery|May 10, 2002
Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosaceaJ K L Tan, C Girard, A Krol, et al.
The American Journal of Psychiatry|April 1, 1995
Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorderJ D Coplan, L A Papp, J Martinez, et al.
Anticancer Research|May 28, 2011
Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancerR Farkas, E Pozsgai, Sz Bellyei, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Psychiatry Research|May 1, 1989
Arterial blood gas changes in panic disorder and lactate-induced panicL A Papp, J M Martinez, D F Klein, et al.
American Journal of Clinical Dermatology|May 27, 2026
Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label StudyJoel C Joyce, H Chih-Ho Hong, Dareen D Siri, et al.
Dermatology and Therapy|August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation AnalysisApril W Armstrong, Peter Foley, Yan Liu, et al.
Pageof 47

Showing results (241-250 of 461) with videos related to

Sort By:
Pageof 47
Journal of the American Academy of Dermatology|July 17, 2017
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)Andrew Blauvelt, Kim A Papp, Mark G Lebwohl, et al.
Journal of Cutaneous Medicine and Surgery|May 10, 2002
Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosaceaJ K L Tan, C Girard, A Krol, et al.
The American Journal of Psychiatry|April 1, 1995
Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorderJ D Coplan, L A Papp, J Martinez, et al.
Anticancer Research|May 28, 2011
Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancerR Farkas, E Pozsgai, Sz Bellyei, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Psychiatry Research|May 1, 1989
Arterial blood gas changes in panic disorder and lactate-induced panicL A Papp, J M Martinez, D F Klein, et al.
American Journal of Clinical Dermatology|May 27, 2026
Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label StudyJoel C Joyce, H Chih-Ho Hong, Dareen D Siri, et al.
Dermatology and Therapy|August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation AnalysisApril W Armstrong, Peter Foley, Yan Liu, et al.
Pageof 47